Emphasizing on the potential role of Nf1 loss in resistance to BRAF and EGFR inhibitors, they also suggested this could be a potential strategy for other cancer types with related changes to the NF1-FAK1 pathway [138]. The gene discussed is NF1; the disease is cancer.